# Phase 1/2 anemia trials recruiting: 41 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 1/2 for anemia that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 anemia trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/anemia

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 1, 2026 | NCT07796620 | Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI | Peking University People's Hospital | Phase 1/2 | Not yet recruiting | Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796620) |
| August 12, 2026 | NCT07761533 | PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS | Chaser Therapeutics, Inc. | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), MDS (Myelodysplastic Syndrome) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761533) |
| July 31, 2026 | NCT07738822 | A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA | Cullinan Therapeutics Inc. | Phase 1/2 | Not yet recruiting | Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738822) |
| July 20, 2026 | NCT07714512 | Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | Aplastic Anemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714512) |
| July 17, 2026 | NCT07712562 | A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse, Severe... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712562) |
| July 16, 2026 | NCT07708714 | Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study | Children's Hospital Medical Center, Cincinnati | Phase 1/2 | Recruiting | Sickle Cell Disease, Sickle Cell Anemia in Children | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708714) |
| June 23, 2026 | NCT07663864 | Luspatercept for CIA in AML | Guangdong Second Provincial General Hospital | Phase 1/2 | Recruiting | Chemotherapy-inducing Anemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663864) |
| June 15, 2026 | NCT07648043 | Feasibility and Acceptability of Amani | Massachusetts General Hospital | Phase 1/2 | Not yet recruiting | Sickle Cell Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648043) |
| May 20, 2026 | NCT07599176 | Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors | National Heart, Lung, and Blood Institute (NHLBI) | Phase 1/2 | Recruiting | Sickle Cell Disease, Beta-thalassemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599176) |
| April 16, 2026 | NCT07532824 | Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS | Institute of Hematology and Blood Transfusion, Czech Republic | Phase 1/2 | Recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Proton Therapy, MDS and AML Prior to Allogeneic SCT... | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532824) |
| March 13, 2026 | NCT07471516 | Zoledronic Acid Treatment in Patients With Congenital Dyserythropoietic Anemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | Congenital Dyserythropoietic Anemia (CDA) | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471516) |
| February 25, 2026 | NCT07432867 | Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected... | Assistance Publique - Hôpitaux de Paris | Phase 1/2 | Recruiting | Sickle Cell Disease | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432867) |
| February 13, 2026 | NCT07408583 | Prenatal Transplantation for Fetuses With Fanconi Anemia | Sponsor not shown (see the record) | Phase 1/2 | Not yet recruiting | Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07408583) |
| January 23, 2026 | NCT07362095 | Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) | Zhujiang Hospital | Phase 1/2 | Recruiting | Acute Leukemia | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07362095) |
| January 14, 2026 | NCT07341022 | STEM CELL MOBILIZATION WITH HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE | Hospital Israelita Albert Einstein | Phase 1/2 | Not yet recruiting | Sickle Cell Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341022) |
| December 22, 2025 | NCT07297550 | Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Not yet recruiting | Severe Aplastic Anemia, Refractory Aplastic Anemia, Newly Diagnosed Aplastic Anemia | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297550) |
| December 17, 2025 | NCT07287228 | The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia | Institute of Hematology & Blood Diseases Hospital, China | Phase 1/2 | Recruiting | Aplastic Anemia, Refractory, Relapse | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287228) |
| December 15, 2025 | NCT07281781 | Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow | University of California, Irvine | Phase 1/2 | Recruiting | Myelofibrosis, Myelofibrosis; Anemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281781) |
| November 26, 2025 | NCT07252050 | Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease | Arkansas Children's Hospital Research Institute | Phase 1/2 | Recruiting | Sickle Cell Disease, Hematopoetic Stem Cell Transplant, Haploidentical Hematopoietic Stem Cell Transplant... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252050) |
| September 16, 2025 | NCT07175493 | A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | Keymed Biosciences Co.Ltd | Phase 1/2 | Recruiting | Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome | 158 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07175493) |
| April 16, 2025 | NCT06930703 | Cannabidiol in Sickle Cell Disease | Icahn School of Medicine at Mount Sinai | Phase 1/2 | Recruiting | Sickle Cell Disease | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930703) |
| February 21, 2025 | NCT06839456 | Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT | Children's Hospital of Philadelphia | Phase 1/2 | Recruiting | Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia, MDS... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06839456) |
| February 11, 2025 | NCT06818838 | A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease | Lingyi Biotech Co., Ltd. | Phase 1/2 | Recruiting | Gaucher Disease Type 1 | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06818838) |
| January 24, 2025 | NCT06791824 | Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia | Keymed Biosciences Co.Ltd | Phase 1/2 | Not yet recruiting | Aplastic Anemia | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06791824) |
| November 8, 2024 | NCT06680752 | Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | ARCE Therapeutics, Inc. | Phase 1/2 | Recruiting | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06680752) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| Fred Hutchinson Cancer Center | 2 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Guangdong Second Provincial General Hospital | 1 |
| Washington University School of Medicine | 1 |
| Hospital Israelita Albert Einstein | 1 |
| Peking University People's Hospital | 1 |
| Children's Hospital of Philadelphia | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Essen Biotech | 1 |
| University of California, Irvine | 1 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 1 |
| Chaser Therapeutics, Inc. | 1 |
| Emory University | 1 |
| Zhujiang Hospital | 1 |
| Kamau Therapeutics | 1 |
| Institute of Hematology and Blood Transfusion, Czech Republic | 1 |
| Disc Medicine, Inc | 1 |
| Cullinan Therapeutics Inc. | 1 |
| Lingyi Biotech Co., Ltd. | 1 |
| Children's Hospital Medical Center, Cincinnati | 1 |
| ARCE Therapeutics, Inc. | 1 |
| Arkansas Children's Hospital Research Institute | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 10 |
| France | 2 |
| Canada | 1 |
| Italy | 1 |
| United Kingdom | 1 |
| Germany | 1 |
| Spain | 1 |
| Brazil | 1 |
| Turkey (Türkiye) | 1 |
| Czechia | 1 |
| Australia | 1 |
| Uganda | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Water softening equipment suppliers in the United States](https://specstream.ai/data/businesses/water-softening-equipment-suppliers/united-states)
- [Home insurance agencies in the United States](https://specstream.ai/data/businesses/home-insurance-agencies/united-states)
- [Vending machine suppliers in the United States](https://specstream.ai/data/businesses/vending-machine-suppliers/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
